In this page we have put a list, which is not exhaustive, of studies on the effects of Zeolit PMA (in Romania, the only Zeolit PMA is Zeolit Spectrum) and AHCC.

1. Zeolite and anticarcinogenic effects in vitro and in vivo

Title: Natural zeolite clinoptilolite: new adjuvant in anticancer therapy
Authors: Pavelić K et al.
Published in: Journal of Molecular Medicine, 2001

Summary:
Micronized clinoptilolite had significant anticarcinogenic effects in cell culture and animal models (mice). It reduced the development of metastases and had an immunomodulatory role. The authors concluded that zeolite could be used as an adjuvant in cancer therapies.

2. PMA zeolite and the immune system in oncology

Title: PMA-zeolite treatment is safe and could act as a modulator of the immune system in cancer patients
Authors: Kraljević Pavelić S. et al.
Published in: Journal of Molecular Medicine, 2018

Summary:
This pilot clinical trial evaluated PMA zeolite (thermally and mechanically activated zeolite) in oncologic patients. It showed good safety, no significant adverse reactions and indications of possible immune system modulation.

3. PMA zeolite and chemotherapy

Title: PMA-Zeolite: Chemistry and Diverse Medical Applications
Authors: Alexandra Bulog. et al.
Published in: Journal of Molecular Medicine, 2018

Abstract: Recently, PMA zeolite has been tested in various clinical applications and has shown potential as an adjuvant therapy in inflammatory disorders, osteoporosis, and during tumor chemotherapy.

4. Effect of AHCC on adverse events of chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

• Title: Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Unresectable Pancreatic Ductal Adenocarcinoma
• Authors: Yanagimoto H. et al.
• Published in: Nutrition and Cancer, 2016

Summary: This study evaluated the effects of AHCC on gemcitabine chemotherapy-induced adverse events in patients with unresectable pancreatic ductal adenocarcinoma. The results showed that AHCC can significantly reduce hematologic and non-hematologic adverse events, contributing to the maintenance of patients' quality of life during treatment.

5. Effect of AHCC on adverse events of chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

• Title: Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment
• Authors: Hashimoto D. et al.
• Published in: Trials, 2022

Summary: This phase II, double-blind, randomized, double-blind, phase II trial aims to evaluate the impact of AHCC on survival in patients with resectable or borderline resectable pancreatic ductal ductal cancer. Patients will receive AHCC or placebo starting on the first day of neoadjuvant therapy and continuing up to two years after surgery. The primary objective is disease-free survival at two years.

6. The effect of AHCC in women receiving adjuvant chemotherapy for breast cancer

• Titlu: Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study
• Authors: Hangai S. et al.
• Published in: Journal of Alternative and Complementary Medicine, 2013

Summary: Retrospective study analyzed the effects of AHCC on adverse events in women receiving adjuvant chemotherapy for breast cancer. Results indicated that AHCC may significantly reduce the incidence of neutropenia and the need for granulocyte colony-stimulating factor, suggesting a potential benefit in ameliorating chemotherapy side effects.

7. Adjuvant effects of AHCC in immunotherapy with checkpoint inhibitors (mouse studies)

• Title: AHCC^®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
• Authors: Hong Jai-Park et al.
• Published in: Frontiers, 2022

Abstract: This study shows that oral administration of AHCC together with a CTLA-4/PD-1 dual blockade treatment (as nivolumab/ipilimumab) in mice with colon tumors (MC38) a:

• significantly reduced tumor volume,
• increased the expression of activation and cytotoxicity markers (granzyme B, Ki-67) in CD8+ T cells in the tumor,
• favorably altered gut microbiome, associated with better immune responses

8. Ameliorating effect of AHCC on adverse effects induced by anticancer drugs in tumor-free mice

In this study, the role of AHCC in reducing the side effects induced by other anticancer drugs was explored in tumor-free mice treated with either paclitaxel (TAX) monotherapy or combined chemotherapy regimens: TAX + CDDP, 5-fluorouracil (5FU) + irinotecan, CDDP + 5FU or doxorubicin + cyclophosphamide.

Results of the drug-treated groups, with and without AHCC supplementation, were compared with the control group that received vehicle alone. Combination treatments significantly reduced medullary cell viability in all groups and leukocyte counts (except the TAX + CDDP group); these myelosuppressive effects were generally ameliorated by AHCC. Hepatotoxicity and nephrotoxicity caused by treatments including TAX and CDDP were also significantly reduced by AHCC.

Mortality rates were between 20 and 30% in all treated groups except TAX + CDDP, and AHCC supplementation greatly reduced or even eliminated mortality.

These results support the idea that AHCC may be beneficial for cancer patients undergoing chemotherapy treatments.